Taylor S G, Desai S A, DeWys W D
Cancer Treat Rep. 1978 Aug;62(8):1203-5.
Twenty patients with advanced colon cancer were treated with a combination of low-dose weekly cyclophosphamide, vincristine, and methotrexate (COM) after demonstrated progression of disease with 5-fluorouracil (5-FU). Four patients (20%) had partial responses with a median survival of 15 months, six (30%) had disease stabilization for 3--16 months (median survival, 8 months), and ten progressed with a median survival of 5.5 months. All four partial responses and five of six stabilizations occurred in patients with a performance status of 0 or 1. COM appeared well-tolerated and at least as effective as alternative secondary chemotherapy following 5-FU failure.
20例晚期结肠癌患者在接受5-氟尿嘧啶（5-FU）治疗后病情进展，随后接受了低剂量每周一次的环磷酰胺、长春新碱和甲氨蝶呤联合方案（COM）治疗。4例患者（20%）出现部分缓解，中位生存期为15个月；6例（30%）病情稳定3至16个月（中位生存期8个月）；10例病情进展，中位生存期为5.5个月。所有4例部分缓解患者和6例病情稳定患者中的5例，其体能状态均为0或1。COM耐受性良好，在5-FU治疗失败后至少与其他二线化疗方案疗效相当。
